The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

SITC opens calls for nominations for 2022 Steven A. Rosenberg Scholars Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Society for Immunotherapy of Cancer opened calls for nominations for the Steven A. Rosenberg Scholars Award May 1. This award provides $150,000 in funding to advance the research of an early career scientist in the field of immunology and cancer immunotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account